 BELTSVILLE, Md., Oct. 01, 2021 GLOBE NEWSWIRE -- NextCure, Inc. Nasdaq: NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two clinical studies and one research study will be presented during oral and poster sessions at the Society for Immunotherapy of Cancer SITC annual meeting, to be held in Washington, D.C., and in a virtual platform on November 10-14, 2021. The data come from clinical studies evaluating NC318, a Siglec-15 antibody, and NC410, a LAIR-2 fusion protein, in patients with advancedmetastatic solid tumors. In addition, in collaboration with the National Cancer Institute at the National Institutes of Health, non-clinical data will be presented from a research study evaluating NC410s impact on T cell activation, myeloid cell polarization and anti-tumor activity. 